04.16.13
Cytovance Biologics, Inc. is expanding its microbial manufacturing capabilities with the purchase of a second 100L and a 1000L Fermenter, along with applicable processing and downstream equipment upgrades to support this larger scale. Facility expansion plans to house these new systems are currently underway.
"This increase in microbial manufacturing capacity is to meet growing customer demands for microbial fermentation services," said Darren Head, Cytovance president and chief executive officer. "This marks another milestone in our contract manufacturing strategy of providing clinical material to key clients as they move though the clinic and into commercial manufacturing."
Cytovance also recently expanded its mammalian manufacturing capabilities with the inclusion of a 5000L stainless steel bioreactor, complimenting its existing manufacturing process trains that include 100L, 500L and 1,000L bioreactors, 100L wave system and 50L and 200L Sartorius subs.
"This increase in microbial manufacturing capacity is to meet growing customer demands for microbial fermentation services," said Darren Head, Cytovance president and chief executive officer. "This marks another milestone in our contract manufacturing strategy of providing clinical material to key clients as they move though the clinic and into commercial manufacturing."
Cytovance also recently expanded its mammalian manufacturing capabilities with the inclusion of a 5000L stainless steel bioreactor, complimenting its existing manufacturing process trains that include 100L, 500L and 1,000L bioreactors, 100L wave system and 50L and 200L Sartorius subs.